+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years - 75Years
All Genders
ID07291401

Study of Neoadjuvant Radiotherapy, CAPOX Chemotherapy, and Iparomlimab with Tuvonralimab QL1706 for Locally Advanced Rectal Cancer

Led by Zhongnan Hospital · Updated on 2026-09-21

108

Participants Needed

1

Research Sites

104 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are investigating the use of radiotherapy combined with CAPOX chemotherapy and two immunotherapy drugs, iparomlimab and tuvonralimab QL1706, as a pre-surgery treatment for patients with locally advanced rectal cancer. This phase II clinical trial aims to improve tumor response rates, including complete pathological response, and to explore how biomarkers in blood and tumor tissue relate to treatment effectiveness. The study focuses especially on patients with microsatellite stable disease, where immunotherapy benefits are less clear. Participants receive pelvic radiotherapy with a possible adaptive boost, along with one cycle of CAPOX chemotherapy during the first week. Two weeks after radiotherapy, they receive four cycles of combined immunotherapy and chemotherapy every three weeks. Surgery to remove the tumor is performed two to three weeks after completing immunochemotherapy, followed by additional CAPOX chemotherapy as adjuvant treatment. The trial will assess response rates and safety throughout these phases. During the study, participants undergo regular assessments including tumor response evaluations, pathological examinations after surgery, and monitoring of adverse events. Key outcomes include pathological and clinical complete response rates, tumor regression, sphincter preservation, and survival rates over three years. Safety and tolerability are evaluated based on established adverse event criteria. The total participation period extends until study completion in 2029, with primary outcomes assessed one year after treatment.

CONDITIONS

Brief Title

Radiotherapy Plus CAPOX, and Iparomlimab and Tuvonralimab (QL1706) as Neoadjuvant Therapy for LARC

Research Team

Y

Yongchang Wei

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here